{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T04:54:05Z","timestamp":1787115245779,"version":"build-2736575974"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,2,20]],"date-time":"2018-02-20T00:00:00Z","timestamp":1519084800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s00417-018-3929-5","type":"journal-article","created":{"date-parts":[[2018,2,20]],"date-time":"2018-02-20T13:57:34Z","timestamp":1519135054000},"page":"1325-1332","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Salvage proton beam therapy for recurrent iris melanoma: outcome and side effects"],"prefix":"10.1007","volume":"256","author":[{"given":"Aline I.","family":"Riechardt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian P.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dino","family":"Cordini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Heufelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matus","family":"Rehak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Seibel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia M.","family":"Joussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,20]]},"reference":[{"key":"3929_CR1","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1177\/112067219300300402","volume":"3","author":"OA Jensen","year":"1993","unstructured":"Jensen OA (1993) Malignant melanoma of the iris: a 25-year analysis of Danish cases. Eur J Ophthalmol 3:181\u2013188","journal-title":"Eur J Ophthalmol"},{"key":"3929_CR2","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.ophtha.2012.09.042","volume":"120","author":"CL Shields","year":"2013","unstructured":"Shields CL, Kaliki S, Hutchinson A, Nickerson S, Patel J, Kancherla S, Peshtani A, Nakhoda S, Kocher K, Kolbus E, Jacobs E, Garoon R, Walker B, Rogers B, Shields JA (2013) Iris nevus growth into melanoma: analysis of 1611 consecutive eyes: the ABCDEF guide. Ophthalmology 120:766\u2013772","journal-title":"Ophthalmology"},{"key":"3929_CR3","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/ICU.0000000000000041","volume":"25","author":"CL Shields","year":"2014","unstructured":"Shields CL, Manalac J, Das C, Ferguson K, Shields JA (2014) Choroidal melanoma: clinical features, classification, and top 10 pseudomelanomas. Curr Opin Ophthalmol 25:177\u2013185","journal-title":"Curr Opin Ophthalmol"},{"key":"3929_CR4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1001\/archophthalmol.2011.286","volume":"130","author":"S Khan","year":"2012","unstructured":"Khan S, Finger PTYGP, Razzaq L, Jager MJ, de Keizer RJ, Sandkull P, Seregard S, Gologorsky D, Schefler AC, Murray TG, Kivel\u00e4 T, Giuliari GP, McGowan H, Simpson ER, Corriveau C, Coupland SE, Damato BE (2012) Clinical and pathologic characteristics of biopsy-proven iris melanoma. A multicenter international study. Arch Ophthalmol 130:57\u201364","journal-title":"Arch Ophthalmol"},{"key":"3929_CR5","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/j.ophtha.2015.01.026","volume":"122","author":"CL Shields","year":"2015","unstructured":"Shields CL, Kaliki S, Furuta M, Fulco E, Alarcon C, Shields JA (2015) American Joint Committee on cancer classification of uveal melanoma (anatomic stage) predicts prognosis in 7,731 patients: the 2013 Zimmerman lecture. Ophthalmology 122:1180\u20131886","journal-title":"Ophthalmology"},{"key":"3929_CR6","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/S0161-6420(00)00449-8","volume":"108","author":"CL Shields","year":"2001","unstructured":"Shields CL, Shields JA, Materin M, Gershenbaum E, Singh AD, Smith A (2001) Iris melanoma: risk factors for metastasis in 169 consecutive patients. Ophthalmology 108:172\u2013178","journal-title":"Ophthalmology"},{"key":"3929_CR7","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ophtha.2012.08.016","volume":"120","author":"JW Harbour","year":"2013","unstructured":"Harbour JW, Wilson D, Finger PT, Worley LA, Onken MD (2013) Gene expressing profiling of iris melanomas. Ophthalmology 120:213","journal-title":"Ophthalmology"},{"key":"3929_CR8","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1136\/bjo.85.7.848","volume":"85","author":"RM Conway","year":"2001","unstructured":"Conway RM, Chua WC, Qureshi C, Billson FA (2001) Primary iris melanoma: diagnostic features and outcome of conservative surgical treatment. Br J Ophthalmol 85:848\u2013854","journal-title":"Br J Ophthalmol"},{"key":"3929_CR9","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/S0002-9394(02)02241-9","volume":"135","author":"CL Shields","year":"2003","unstructured":"Shields CL, Naseripour M, Shields JA, Freire J, Cater J (2003) Custom-designed plaque radiotherapy for nonresectable iris melanoma in 38 patients: tumor control and ocular complications. Am J Ophthalmol 135:648\u2013656","journal-title":"Am J Ophthalmol"},{"key":"3929_CR10","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1007\/s00417-014-2735-y","volume":"252","author":"A Rahmi","year":"2014","unstructured":"Rahmi A, Mammar H, Thariat J, Angellier G, Herault J, Chauvel P, Kodjikian L, Denis P, Grange JD (2014) Proton beam therapy for presumed and confirmed iris melanomas: a review of 36 cases. Graefes Arch Clin Exp Ophthalmol 252:1515\u20131521","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3929_CR11","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.ophtha.2017.02.015","volume":"124","author":"SS Chaugule","year":"2017","unstructured":"Chaugule SS, Finger PT (2017) Regression patterns of iris melanoma after Palladium-103 (103Pd) plaque brachytherapy regression patterns of iris melanoma after Palladium-103 (103Pd) plaque brachytherapy. Ophthalmology 124:1023\u20131030","journal-title":"Ophthalmology"},{"key":"3929_CR12","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1136\/bjophthalmol-2012-302659","volume":"97","author":"L Konstantinidis","year":"2013","unstructured":"Konstantinidis L, Roberts D, Errington RD, Kacperek A, Damato B (2013) Whole anterior segment proton beam radiotherapy for diffuse iris melanoma. Br J Ophthalmol 97:471\u2013474","journal-title":"Br J Ophthalmol"},{"key":"3929_CR13","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1136\/bjophthalmol-2017-310278","volume":"102","author":"U Agraval","year":"2018","unstructured":"Agraval U, Sobti M, Russell HC, Lockington D, Ritchis D, Cauchi P, Kemp EG, Chadha V (2018) Use of Ruthenium-106 brachytherapy for iris melanoma: the Scottish experience. Br J Ophthalmol 102:74\u201378","journal-title":"Br J Ophthalmol"},{"key":"3929_CR14","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.ophtha.2011.09.039","volume":"119","author":"SU Shah","year":"2012","unstructured":"Shah SU, Shields CL, Bianciotto C, Emrich J, Komarnicky L, Shields JA (2012) Plaque radiotherapy for residual or recurrent iris melanoma after surgical resection in 32 cases. Ophthalmology 119:838\u2013842","journal-title":"Ophthalmology"},{"key":"3929_CR15","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s00066-017-1166-1","volume":"193","author":"AI Riechardt","year":"2017","unstructured":"Riechardt AI, Karle B, Cordini D, Heufelder J, Budach V, Joussen AM, Gollrad J (2017) Proton therapy of iris melanoma with 50\u00a0CGE: influence of target volume on clinical outcome. Strahlenther Onkol 193:943\u2013950","journal-title":"Strahlenther Onkol"},{"key":"3929_CR16","volume-title":"AJCC cancer staging manual","year":"2017","unstructured":"Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, Jessup JM, Brierley JD, Gaspar LA, Schilsky RL, Balch CM, Winchester DP, Asare EA, Madera M, Gress DM, Meyer LR (eds) (2017) AJCC cancer staging manual, 8th edn. Springer International Publishing, New York","edition":"8"},{"key":"3929_CR17","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1136\/bjophthalmol-2014-305174","volume":"99","author":"GD Willerding","year":"2015","unstructured":"Willerding GD, Cordini D, Hackl C, Karle B, Lakotka N, Foerster MH, Bechrakis NN, Heufelder J, Moser L, Joussen AM (2015) Proton beam radiotherapy of diffuse iris melanoma in 54 patients. Br J Ophthalmol 99:812\u2013816","journal-title":"Br J Ophthalmol"},{"key":"3929_CR18","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1118\/1.595258","volume":"10","author":"M Goitein","year":"1983","unstructured":"Goitein M, Miller T (1983) Planning proton therapy of the eye. Med Phys 10:275\u2013283","journal-title":"Med Phys"},{"key":"3929_CR19","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/978-3-642-59758-9_124","volume-title":"The use of computers in radiation therapy","author":"K Pfeiffer","year":"2000","unstructured":"Pfeiffer K, Dobler B, Rethfeldt C, Schlegel W, Bendl R (2000) OCTOPUS, a planning tool for proton therapy of eye tumours. In: Schlegel W, Bortfeld T (eds) The use of computers in radiation therapy. Springer, Berlin, pp 329\u2013331"},{"key":"3929_CR20","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ophtha.2015.09.014","volume":"123","author":"Ophthalmic Oncology Task Force","year":"2016","unstructured":"Ophthalmic Oncology Task Force (2016) Local recurrence significantly increases the risk of metastatic uveal melanoma. Ophthalmology 123:86\u201391","journal-title":"Ophthalmology"},{"key":"3929_CR21","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1136\/bjo.80.2.109","volume":"80","author":"BE Damato","year":"1996","unstructured":"Damato BE, Paul J, Foulds WS (1996) Risk factors for metastatic uveal melanoma after trans-scleral local resection. Br J Ophthalmol 80:109\u2013116","journal-title":"Br J Ophthalmol"},{"key":"3929_CR22","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/1479-5876-10-179","volume":"10","author":"M Carbone","year":"2012","unstructured":"Carbone M, Ferris LK, Baumann F, Napolitano A, Lum CA, Flores EG, Gaudino G, Powers A, Bryant-Greenwood P, Krausz T, Hyjek E, Tate R, Friedberg J, Weigel T, Pass HI, Yang H (2012) BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J Transl Med 10:179","journal-title":"J Transl Med"},{"key":"3929_CR23","doi-asserted-by":"publisher","first-page":"e577","DOI":"10.1111\/j.1755-3768.2012.02389.x","volume":"90","author":"L Razzaq","year":"2012","unstructured":"Razzaq L, Marinkovic M, Jager MJ, Bleeker J, Luyten GP, de Keizer RJ (2012) Letters to the editor: corneal endothelial cell density after ruthenium plaque radiation therapy for iris melanoma patients. Acta Ophthalmol 90:e577\u2013e579","journal-title":"Acta Ophthalmol"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00417-018-3929-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-018-3929-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-018-3929-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,19]],"date-time":"2019-02-19T19:13:28Z","timestamp":1550603608000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00417-018-3929-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,20]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["3929"],"URL":"https:\/\/doi.org\/10.1007\/s00417-018-3929-5","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,20]]},"assertion":[{"value":"18 May 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"A.I. Riechardt: reimbursements of travel expense: EURETINA 2015\/Novartis. J.P. Klein states that there are no conflicts of interest. D. Cordini states that there are no conflicts of interest. J. Heufelder states that there are no conflicts of interest. M. Rehak: board membership: Novartis, Allergan, Alimera, speaker honoraria: Novartis Bayer, Allergan, Alimera. I. Seibel states that there are no conflicts of interest. Prof. A. M. Joussen states that there are no conflicts of interest. The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the institutional review board of the Charit\u00e9-Universit\u00e4tsmedizin Berlin, Berlin, Germany, and was in accordance with the tenets of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}